AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

Delisting risk

FEMY · NASDAQ · Medical - Instruments & Supplies

Femasys (FEMY)

Catheter-based fertility diagnostics, treatment, and permanent-contraception development.

$3.11

At close−0.15 (−4.60%)

Watchlist

Something off on this page? Send us feedback.

Breakdown13F · 13D/G · Form 4

Institutions2 holders · as of Jun 30, 2026	0.02%	1.8K shares
Insiders9 holders · as of Aug 11, 2026	0.57%	47.4K shares
Strategic holders1 holder · as of Aug 31, 2026	7.46%	625.0K shares
Otherremainder	91.95%	7.70M shares

8.38M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing

Two share counts disagree (8.38M in the company's Sep 3, 2026 report, 3.02M elsewhere); stakes use the report.

A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.

Top shareholders13F · 13D/G · Form 4

Holder	Stake	Shares	Evidence
Stonepine Capital Management, LLCStrategic	7.46%	625,000	13Gfiled Aug 31, 2026 ↗
Dov ElefantInsiderofficer: Chief Financial Officer	0.19%	15,625	Form 4filed Aug 11, 2026 ↗
Kathy Lee-SepsickInsiderdirector, officer: Chief Executive Officer	0.19%	15,625	Form 4filed Aug 11, 2026 ↗
John Charles CanningInsiderofficer: Chief Operating Officer	0.05%	4,375	Form 4filed Aug 11, 2026 ↗
Daniel Scott CurrieInsiderofficer: Chief Operating Officer	0.05%	4,314	Form 4filed Jun 4, 2025 ↗
Jeffrey Gerald MifekInsiderofficer: Chief Clinical-Medical Affairs	0.04%	3,125	Form 4filed Aug 11, 2026 ↗
Jeremy Alexander SiposInsiderofficer: Chief Technology Officer	0.04%	3,125	Form 4filed Aug 11, 2026 ↗
Kenneth D. EichenbaumInsiderdirector	0.01%	1,251	Form 4filed Mar 24, 2026 ↗
Ifp Advisors, IncInstitution	0.01%	1,000	13Fas of Jun 30, 2026
CX InstitutionalInstitution	0.01%	750	13Fas of Jun 30, 2026
Kelley Stinson NicholasInsiderofficer: Chief Commercial Officer	0.00%	6	Form 4filed Jul 1, 2025 ↗
Charles LarsenInsiderdirector	0.00%	3	Form 4filed Jun 4, 2025 ↗
Alumni Capital LPInstitution	—9.99% of class, as filed	—	13Gfiled Sep 4, 2025 ↗
Chernett JoreyInsider	—9.30% of class, as filed	—	13Gfiled Aug 5, 2025 ↗
Dauntless Investment Group, LLCStrategic	—9.90% of class, as filed	—	13Gfiled Nov 14, 2025 ↗
Nantahala Capital Management, LLCInstitution	—9.99% of class, as filed	—	13Dfiled Aug 17, 2026 ↗
PharmaCyte Biotech, Inc.Strategic	—7.87% of class, as filed	—	13Gfiled Mar 18, 2026 ↗
Rosalind Advisors, Inc.Strategic	—9.90% of class, as filed	—	13Gfiled Aug 14, 2026 ↗
John Q. JR Adams¹Insiderdirector	0.14%	11,997	Form 4filed Jun 24, 2021 ↗
Edward R. Uzialko¹Insiderdirector	0.02%	1,509	Form 4filed Jun 24, 2021 ↗
William Benson Witte²Insiderdirector	0.01%	610	Form 4filed Dec 17, 2021 ↗
Gary Thompson³Insiderdirector	0.00%	167	Form 4filed Jun 17, 2021 ↗
John Dyett²Insiderdirector	0.00%	0	Form 4filed Dec 17, 2021 ↗

Last filed Jun 24, 2021; leaving the company requires no filing. Not in the bar.
Last filed Dec 17, 2021; leaving the company requires no filing. Not in the bar.
Last filed Jun 17, 2021; leaving the company requires no filing. Not in the bar.

13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report

Institutions13F, as of Jun 30, 2026

2 holders · 1.8K shares

Holder	Shares	% outstanding	Chg q/q	Filed
Ifp Advisors, Inc	1.0K	0.01%		Jul 20, 2026
CX Institutional	750	0.01%		Jul 2, 2026

Ownership statements13D/G · 5% or more, as filed

Holder	% of class	Shares	Form	Filed
Nantahala Capital Management, LLCincl. Daniel Mack, Wilmot B. Harkey +1 more	9.99%	803.0K	13D	Aug 17, 2026 ↗
Alumni Capital LP	9.99%		13G	Sep 4, 2025 ↗
Rosalind Advisors, Inc.	9.90%		13G	Aug 14, 2026 ↗
Dauntless Investment Group, LLC	9.90%		13G	Nov 14, 2025 ↗
Chernett Jorey	9.30%		13G	Aug 5, 2025 ↗
PharmaCyte Biotech, Inc.	7.87%		13G	Mar 18, 2026 ↗
Stonepine Capital Management, LLC	7.20%	625.0K	13G	Aug 31, 2026 ↗

Insider tradesForm 4

Latest trades

Date	Insider	Type	Shares	Avg price	Owned after
Aug 7, 2026	Jeffrey Gerald Mifekofficer: Chief Clinical-Medical Affairs	Purchase	3,125	$3.20	3,125
Aug 7, 2026	Jeremy Alexander Siposofficer: Chief Technology Officer	Purchase	3,125	$3.20	3,125
Aug 7, 2026	John Charles Canningofficer: Chief Operating Officer	Purchase	4,375	$3.20	4,375
Aug 7, 2026	Kathy Lee-Sepsickdirector, officer: Chief Executive Officer	Purchase	15,625	$3.20	15,625
Aug 7, 2026	Dov Elefantofficer: Chief Financial Officer	Purchase	15,625	$3.20	15,625

CongressHouse and Senate disclosures

Not reported.